#China #Qingdao #Global Sales #Lab Equipment #Haier Biomedical

Haier Biomedical: Leading the Lab Equipment Market

Haier Biomedical, a prominent player in the laboratory equipment sector, has recently achieved a remarkable milestone by being named the number one Chinese brand in global sales of life science lab equipment according to Euromonitor International's report for 2025. This accolade not only underscores Haier Biomedical's dominance in the market but also highlights its significant growth during a meticulously planned three-phase international expansion strategy.

The importance of these rankings cannot be understated; they are derived from comprehensive global sales figures, including foreign revenue generated by Chinese-owned brands operating within this competitive field. As Haier Biomedical stands tall among reputable international manufacturers, it has established itself as a trustworthy figure in an industry where reliability, compliance, and long-term service maintenance are critical factors influencing purchasing decisions.

A Focused Expansion

Haier Biomedical's journey into international markets has been strategic, starting with projects aimed at specific unmet needs, collaborating directly with organizations like UNICEF and the World Health Organization to provide solar-powered vaccine storage solutions. This targeted approach has not only facilitated brand recognition but has also enabled the company to build a robust distribution network that spans over 160 countries, supported by more than 800 active business relationships.

In the current phase of its expansion, Haier Biomedical focuses on enhancing operational capabilities within key markets. This includes setting up local storage, sales, marketing, product planning, and research and development facilities. Its foreign R&D centers in the UK, Italy, and Japan specialize in various product lines such as centrifuges, cold chain solutions, automated storage systems, incubators, and biological safety cabinets. Such expertise ensures compliance with Good Manufacturing Practices (GMP) while also guaranteeing air safety and sample purification, making Haier Biomedical a trusted partner in laboratory operations.

Significant Revenue Growth

The company's exceptional service standards, first established in the USA and the UK, have been recently implemented across Europe, Southeast Asia, and South Asia. As a result, Haier Biomedical has witnessed extraordinary revenue growth in Q1 2026, with increases exceeding 50% in Germany, Australia, and Canada. In Eastern Europe, South Asia, and Brazil, year-on-year growth surpassed 100%, with sales volumes of centrifuges and incubators doubling.

In the pharmaceutical sector, Haier Biomedical is a critical contributor to the supply chains of leading pharmaceutical firms across key countries, including Switzerland, Germany, Denmark, Italy, Singapore, the United States, Israel, and India. Notably, the Ultra Energy series of products occupies all eight top positions in the U.S. Energy Star rankings within its category, reaffirming its status as the best-selling line in this segment.

Future Outlook

Looking ahead, Haier Biomedical is poised to deepen its commitment to localization and enhance its product offerings. The company’s vision entails supporting global biopharmaceutical and life science laboratories to improve efficiencies and sustainability measures, all while maintaining a leadership role in delivering integrated tools and intelligent productivity platforms.

To learn more about Haier Biomedical’s innovative solutions and their impact on the life sciences sector, be sure to visit their official website at Haier Biomedical.